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patient’s 30-day BP proﬁle was simulated and an individual
correction factor estimated. Each patient’s correction factor was
calculated by dividing the mean of their simulated BP reduction
by the BP reduction achieved with no dosing errors. For each
treatment, the overall correction factor was derived by averaging
the individual correction factors. RESULTS: The much slower
rise in BP after stopping aliskiren, and the high prevalence of
missed doses, led to substantially different correction factors.
CONCLUSIONS: These ﬁndings suggest that once-daily drugs
differ in the extent to which they lower BP in real life, in which
missed doses happen frequently. When differences in correction
factors are applied to drugs with similar efﬁcacy, they can reveal
meaningful (1–3 mmHg systolic BP) differences in real life
effectiveness.
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OBJECTIVES: The purpose of the present study was to investi-
gate, the impact f drug-eluting stents (DES) vs. bare metal stent
(BMS) implantation on the incidence of major adverse cardio-
vascular events in patients with real conditions on the occur-
rence of short-and long term, of stent thrombosis, myocardial
infarction, need for repeat revascularization and clinical symp-
toms and death. METHODS: Since March 1, 2006 to September
31, 2007 a total of 220 consecutive patients with novo lesions
exclusively treated with DES unrestricted use vs. bare metal
stents and 1 year a follow-up. In a cohort of patients with
ischemic disease with indication of PCI (Percutaneous Coronary
Intervention). The measure of effectiveness was compared
in-hospital, 6-month, 1-year outcomes in 220 patients who
underwent PCI using DES or BMS. Major adverse cardiac events
(MACE) included: death cardiac, myocardial infarction (MI),
restenosis angiographic (RA), stent thrombosis, target lesion
revascularisation (TLR) was deﬁned as a repeated revascularisa-
tion procedure (either PCI or coronary bypass surgery), as the
result of restenosis in the stented segment. Deﬁnite stent throm-
bosis was included deﬁned as an acute coronary ischemic event
associated to angiographic documentation of occlusion stent.
Statistical Analysis: continuous variables are presented as
mean+SD and were compared by means of the Student unpaired
t-test. Categorical variables are presented as counts and percent-
ages and compared by means of the Fisher exact test and Sur-
vival curve Kaplan Meier. RESULTS: Age BMS 60.01 +- 9.195
vs. DES 56 +- 9.86 value p = 0.026, diabetes, hypertension,
hypercholesterolaemia, current smoking similar. Both groups
were reasonably well matched for baseline characteristics with
exception age. The Expulsion fraction FEVI BMS 49.64 +- 13%
vs. DES 52.19 +- 11.7%, stents implanted BMS 55.1% vs. DES
42.9% with a medium 1.5 stents for patient. Total MACE
(Major adverse cardiac events): 10 (11.4%) vs. 31(24.2%)
p = 0.018, restenosis and need revascularization lesion target
(TLR) BMS 13 (10.2%) vs. DES 2 (1.6%) p = 0.002, thrombosis
6 (4.7%) vs. 0 p = 0.039, angina 2(1.6%) vs. 6 (6.8%)
p = 0.044, death 10 (7.8%) vs. 0 p = 0.007, test positive for
ischemic 3 (2.3%) vs. 1(1.1%) p = 518, required new revascu-
larization BMS 3 (2.3%) vs. DES 3(3.4%) p = 0.64. The baseline
and procedural characteristics reﬂect the complex patient’s. The
survival free events were BMS 74% vs. DES 88 %, the difference
in major adverse cardiac events was driven by the reduction in
the need for repeat revascularization, deﬁned as TVR in the DES
group. CONCLUSIONS: The lower differential effect in real-
world outcomes, together with increased material use compared
with the difference in major adverse cardiac events was driven by
the reduction in the need for repeat revascularization, deﬁned as
TLR in the DES group.
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OBJECTIVES: To explore the efﬁcacy of Angiotensin Receptor
Blockers (ARBs) in reducing blood pressure (BP) compared to
ACE Inhibitors in a real-world setting. METHODS: We analysed
the records of 16,866 (14,651 ACE Inhibitors and 2,215 ARBs)
adult patients with hypertension who were initiated on the agents
between 1998 and 2006 and who remained on that hypertensive
treatment as monotherapy for the duration of their time in the
database. Anonymised patient data were drawn from the UK
THIN general practice database. Hypertension was deﬁned as a
systolic blood pressure (SBP) reading 140 mmHg or diastolic
BP (DBP) 90 mmHg. RESULTS: In a population means
analysis, at 1 year, mean SBP reductions for patients receiving
ARB therapy reached 13.2 mmHg compared to 11.1 mmHg for
patients receiving ACE Inhibitors. For DBP mean reductions for
patients receiving an ARB reached 7.8 mmHg compared to
6.7 mmHg for patients receiving an ACE Inhibitor. At 2 years,
patients’ mean SBP reductions reached 13.6 mmHg for the ARBs
group and 11.2 mmHg for the ACE Inhibitors group. Similar
results were also observed with DBP at 2 years with patients
receiving ARB treatment reaching reductions of 8.3 mmHg com-
pared to 7.1 mmHg reached by patients receiving an ACE Inhibi-
tor. The comparisons were statistically signiﬁcant (p < 0.001) in
a linear mixed multivariate analysis adjusting for repeated mea-
sures and random practice effects conditioning on baseline blood
pressure, age, diabetes status, hypertensive diagnosis status and
number of other non-hypertensive cardiovascular treatments.
CONCLUSIONS: In a real-world setting, patients receiving
ARBs as monotherapy are observed to achieve greater reductions
in blood pressure compared to those receiving ACE Inhibitors as
monotherapy.
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OBJECTIVES: Among patients at high risk for coronary heart
disease (CHD) LDL-C remains the primary lipid treatment
target. However, HDL-C and triglycerides (TG) have also
emerged as modiﬁable risk factors (RF). This study assessed the
attainment of multiple recommended lipid levels among patients
receiving lipid modifying therapy (LMT). METHODS: A retro-
spective clinical chart review of patients treated in primary care
and hospitals was conducted in Spain. High CHD risk patients
(identiﬁed as patients with CHD/CHD equivalent, or 2+ CHD
RF) who had full lipid panels 12 months pre-LMT (baseline), and
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12–36 months post-LMT initiation (follow-up), were included.
Target levels for LDL-C were deﬁned as per NCEP ATP III
guidelines. Recommended levels for HDL-C were >40 mg/dL for
men and >50 mg/dL for women, and <150 mg/dL for TG.
RESULTS: We identiﬁed 556 high CHD risk patients, mean age
63.6 (SD10.6) years and 55.9% patients were male. Ninety-ﬁve
percent had initiated statin mono or combination therapy. Base-
line mean values for LDL-C and HDL-C were 159.5 mg/dL
(SD38.4) and 52.3 mg/dL (SD16.4), respectively. The median TG
level was 140 mg/dL (IQR: 104–198 mg/dL). The reductions in
mean LDL-C, HDL-C and TG from baseline were 26.4%, 0.1%
and 8%, respectively. At follow-up, of the total patients with
LDL-C not at goal (48.9%), 47.1% had only LDL-C not at goal,
52.9% had both LDL-C not at goal and HDL-C and/or TG not
at goal, and 19.4% had all three lipid components not at goal.
CONCLUSIONS: In this cohort of mostly statin-treated high
risk patients, barely half of them had achieved LDL-C target
levels 12–36 months after LMT initiation. Among those with
LDL-C not at goal, about 53% of patients experienced HDL-C
and/or TG also not at goal indicating high prevalence of multiple
lipid disorders.
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OBJECTIVES: Surveys evaluating plasma lipid goal attainment
in coronary heart disease (CHD) patients have shown that hyper-
cholesterolemia is inadequately treated. The aim of this survey
was to evaluate the use and efﬁcacy of lipid lowering drugs (LLD)
and to identify factors associated with failure to reach LDL-C
target. METHODS: CEPHEUS-Greece was part of a European
multi-centre, cross-sectional survey performed during a single
visit in 8 countries and included patients on LLD for 3 months
without a dose change for at least 6 weeks. Fasting lipid samples
were analysed in a central laboratory. Physicians and patients
completed a questionnaire, covering various aspects of hyper-
cholesterolemia. RESULTS: 175 Greek physicians (48.6% in
primary care, 47.4% cardiologists, 4.0% other) recruited con-
secutive patients in 2006–2007. The full analysis set population
comprised 1321 patients. Mean (SD) age was 61.7 (11.3) years
(44.8% females) and waist circumference 96.2 (14.4) cm. 28%
were smokers, while 60.7%, 35.4% and 25.1% of patients had
a history of hypertension, CHD or diabetes, respectively. 83.6%
of patients were on statin monotherapy. 53.9% remained on
their starting dose of LLD with no adjustment. Overall, 49.7%
and 49.3% of patients reached the Third Joint European Task
Force and the 2004-updated NCEP ATP III LDL-C goal, respec-
tively. Only 14.7% of the very high-risk population reached
the 2004-updated NCEP ATP III target (LDL-C < 70 mg/dl or
1.8 mmol/l). Multivariate analyses showed that smoking status
(non-smokers vs smokers, OR: 2.17 [95% CI: 1.59–2.95]) and
history of CHD (no history vs history, OR: 4.89 [95% CI:
3.57–6.69]) were strong determinants for reaching LDL-C target.
CONCLUSIONS: Almost 50% of Greek patients using LLD are
not on target for LDL-C. In addition to lifestyle interventions,
selection of an appropriate treatment strategy, adherence to
guidelines and improvement of patient compliance may have a
signiﬁcant impact on reaching LDL-C target.
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OBJECTIVES: To assess the relationship between statin therapy
on mortality risk in usual care management of elderly.
METHODS: The present study is a population-based, observa-
tional, longitudinal study performed on 59,398 subjects aged 70
years or older, between 2000 and 2005 in Northern France
(266,071 person-years). The data was extracted from a French
administrative managed care database (CANSSM). Survival of
incident persistent statin users was compared to survival of non
lipid-lowering agent (LLA) users, thanks to multivariable Cox
proportional models stratiﬁed on ﬁve-year birth cohorts adjusted
on gender and hospitalizations occurring in 1999. In the same
way, impact of ﬁbrate therapy was explored. Survival of anti-
glaucoma treatment (AG) users versus non AG users was also
assessed as a neutral comparator model. RESULTS: As of
January 1, 2000, 59,398 subjects over 70 years of age were
included in the cohort.. The median age at baseline was 76 years
of age [min: 70 / max: 107]. Overall survival at the end of
follow-up was 79.3% for persistent statin users versus 61.0% for
non LLA users. In the global multivariate Cox model, stratiﬁed
on ﬁve-year birth cohorts and adjusted on gender and hospital-
izations occurring in 1999, the HR for mortality associated with
persistence of statins was 0.71 (95% CI 0.63–0.81; p < 0.0001).
No statistic association was found for the survival of subjects
persistent to ﬁbrate versus non LLA users, nor for persistent AG
users versus non AG users, with respectively HR = 1.05 (95% CI
0.75–1.48, adjusted; p = 0.77) and HR = 0.81 (95% CI 0.63–
1.05, adjusted; p = 0.12). CONCLUSIONS: Although further
investigation must be conducted, in particular on adjustment
variables, the main results of our study suggest a beneﬁcial
impact of persistent statin therapy in reducing all cause mortality
by 29%, in a large cohort of elderly.
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OBJECTIVES: To understand the potential for drug-drug inter-
actions (DDIs) among patients with diabetes and/or hypertension
and multiple other comorbidities. METHODS: Patients were
selected from the 2005 MarketScan databases who had hyperten-
sion and/or diabetes, a chronic disease score in the top 10% of the
cohort, and 12 months of continuous enrollment. Concomitant
medications were identiﬁed from the 12 month follow-up and
tested against the DRUG-REAX system, which is used by phar-
macists to check for potential DDIs and determine their clinical
signiﬁcance. The system includes a severity rating and documen-
tation quality classiﬁcation for the interaction potential. A DDI
was counted when drugs in potentially interacting combinations
with excellent or good documentation were dispensed within 30
days of each other during the time period. RESULTS: A total of
98,844 patients met the study criteria with 79,830 (80.7%) of
them having at least one potential DDI. These patients ﬁlled an
average of 28 prescriptions per year and almost 98% were over
age 64. Among these patients, 306,649 unique, potential DDIs
were identiﬁed with the severity rating distributed as follows:
Contraindicated—0.8%; Major—29.9%; Moderate—61.1%;
Minor 8.3%. Potential DDIs included: potassium chloride in
combination with anticholinergics (contraindicated), potassium
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